Pharmaceutical Technology on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
JetBrains' 2026 developer survey puts Python ahead of JavaScript, with TypeScript leading growth potential and Rust topping ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results